A phase 2a clinical trial evaluating RPL554 compared with placebo as add on to LAMA/LABA therapy for the maintenance treatment of severe COPD
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs RPL 554 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 01 Aug 2018 According to a Verona Pharma media release, first patients have been enrolled and dosed in the study, and top line data are expected in the first quarter of 2019.
- 01 Aug 2018 Status changed from planning to recruiting, as reported in the Verona Pharma media release.
- 08 May 2018 According to a Verona Pharma media release, the company expects to commence this study in 3Q 2018